Home The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
Article
Licensed
Unlicensed Requires Authentication

The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity

  • Iwona Wybrańska , Malgorzata Malczewska-Malec , Sylwia Niedbal , Jerzy W. Naskalski and Aldona Dembińska-Kieć
Published/Copyright: June 1, 2005
Become an author with De Gruyter Brill
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Volume 41 Issue 4

Abstract

Tumour necrosis factor alpha (TNF-α), acting as a modulator of gene expression in adipocytes, has been linked to the development of insulin resistance and obesity. The aim of this study was to investigate whether the A/G variation at position −308 in the TNFα promoter influences the body weight, insulin resistance, and postprandial lipaemia in Polish Caucasians. One hundred twenty one subjects, 38 men and 83 women, representing 40 obese families, were genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). TNF-1 (GG) and TNF-2 (GA and AA) allele carriers were compared with respect to body mass index, fat/lean body mass composition, waist-to-hip ratio, as well as fasting lipids, glucose, leptin, and insulin fasting, and during the oral glucose tolerance test (4 points within 2 hours) and oral lipid tolerance test (OLTT; 5 points within 8 hours). The insulin sensitivity indices HOMA-IR (homeostasis model assessment of insulin resistance), ISI-COMP (whole body insulin sensitivity index), ISI-HOMA (hepatic insulin sensitivity), and DELTA (early secretory response to an oral glucose load) were calculated. We detected 64 GG, 56 GA, and 1 AA genotypes. Significant increases of insulin resistance parameters in obese female TNF-2 allele carriers were observed (significantly increased HOMA-IR and decreased ISI-HOMA, ISI-composite). The male TNF-2 carriers were characterised by significantly increased levels of triglyceride and free fatty acids during OLTT as well as fasting glucose. The A/G variation at position −308 in the promoter region of the TNF-α gene could be an important genetic factor predisposing to insulin resistance in obese women and increased levels of glucose, triglyceride, and free fatty acids in men.

:
Published Online: 2005-06-01
Published in Print: 2003-04-25

Copyright © 2003 by Walter de Gruyter GmbH & Co. KG

Articles in the same Issue

  1. First Santorini Conference: From Genetic Variations to Risk Prediction and Pharmacogenomics
  2. Pharmacogenetics and Pharmacogenomics in Drug Discovery and Development: An Overview
  3. Regulatory Gene Mutations Affecting Apolipoprotein Gene Expression: Functions and Regulatory Behavior of Known Genes May Guide Future Pharmacogenomic Approaches to Therapy
  4. The Proteome: Anno Domini 2002
  5. Cardiac Sodium Channel Diseases
  6. Haemophilia B: From Molecular Diagnosis to Gene Therapy
  7. The Use of Denaturing High-Performance Liquid Chromatography (DHPLC) for the Analysis of Genetic Variations: Impact for Diagnostics and Pharmacogenetics
  8. Molecular Diagnostics by Microelectronic Microchips
  9. Molecular Beacons as Diagnostic Tools: Technology and Applications
  10. Electrochemical DNA Sensor for Detection of Single Nucleotide Polymorphisms
  11. Comparison of Standard PCR and the LightCycler® Technique to Determine the Thrombophilic Mutations: An Efficiency and Cost Study
  12. Impact of Purified Water Quality on Molecular Biology Experiments
  13. Which Are the best Tools for Specific Clinical Application (Chips, Multiplex, Mass Spec Profile, etc.)?
  14. Genetic Variations Observed in Arterial and Venous Thromboembolism – Relevance for Therapy, Risk Prevention and Prognosis
  15. The TNF- α Gene NcoI Polymorphism at Position –308 of the Promoter Influences Insulin Resistance, and Increases Serum Triglycerides after Postprandial Lipaemia in Familiar Obesity
  16. The –308 G/A Tumor Necrosis Factor-α Gene Dimorphism: A Risk Factor for Unstable Angina
  17. The Apolipoprotein AV Gene and Diurnal Triglyceridaemia in Normolipidaemic Subjects
  18. Left Ventricular Size, Mass and Function in Relation to Angiotensin-Converting Enzyme Gene and Angiotensin-II Type 1 Receptor Gene Polymorphisms in Patients with Coronary Artery Disease
  19. Analysis of Multiple Single Nucleotide Polymorphisms of Candidate Genes Related to Coronary Heart Disease Susceptibility by Using Support Vector Machines
  20. PON1-192 Phenotype and Genotype Assessments in 918 Subjects of the Stanislas Cohort Study
  21. Lipoprotein Lipase Gene Polymorphisms in Croatian Patients with Coronary Artery Disease
  22. Homocysteine, Methylenetetrahydrofolate Reductase C677T Polymorphism and the B-Vitamins: A Facet of Nature-Nurture Interplay
  23. Which, and How Limited Number of Polymorphisms Should Be Selected per Disease, Risk Assessment, Health Profile or Biological System?
  24. Ethical Issues: Should We Give the Predictive Genetic Profile to the Citizens?
  25. Pharmacogenetics and Responders to a Therapy: Theoretical Background and Practical Problems
  26. Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine
  27. Pharmacogenomics and Pharmacogenetics of Cholesterol-Lowering Therapy
  28. Pharmacogenomics of Drugs Affecting the Cardiovascular System
  29. Allele Frequencies for Glutathione S-Transferase and N-Acetyltransferase 2 Differ in African Population Groups and May Be Associated With Oesophageal Cancer or Tuberculosis Incidence
  30. CYP3A4*1B and NAT2*14 Alleles in a Native African Population
  31. Pharmacogenetics: From Bench to Bedside
  32. Meetings and Awards
Downloaded on 11.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2003.076/html
Scroll to top button